Dose-response assessment of chemically modified curcumin in experimental periodontitis
- PMID: 30394523
- DOI: 10.1002/JPER.18-0392
Dose-response assessment of chemically modified curcumin in experimental periodontitis
Abstract
Background: CMC2.24, a novel tri-ketonic chemically modified compound based on natural di-ketonic curcumin, has been shown to reduce bone loss and inflammatory mediators in experimental periodontitis, however, a potential dose-response relationship was not determined. The purpose of this study was to assess the effects of different doses of CMC2.24 on inflammation and bone resorption in vivo and also to describe on the effects of CMC2.24 on macrophage response.
Methods: CMC2.24 was administered daily to animals for 28 days by oral gavage, at the following doses: 0 (control), 1, 3, 10, and 30 mg/kg of body weight. Experimental periodontitis was induced by injections of lipopolysaccharide (LPS) into the gingival tissues. Outcomes assessed were bone resorption, detection of tartrate-resistant acid phosphatase, and determination of gene expression. In vitro, macrophages (RAW264.7) were treated with different concentrations of CMC2.24: 1, 3, 10, and 30 μM and then subjected to different activation stimuli. Gene expression, phagocytic activity, production of reactive oxygen species (ROS) and cytokine production were evaluated.
Results: CMC2.24 inhibited bone resorption, osteoclastogenesis, and tumor necrosis factor (TNF)-α expression in vivo. These beneficial responses reached maximum levels at a dose of 1 mg/kg, i.e. no dose-dependent effect. In vitro, CMC2.24 reduced the production of TNF-α and interleukin-10, inhibited phagocytic activity and stimulated production of ROS. A dose-dependent effect was observed only for ROS production.
Conclusion: Low doses of CMC2.24 (1 mg/kg/day) administered orally were sufficient to significantly inhibit alveolar bone resorption associated with the experimental periodontal disease; whereas in vitro macrophage inflammatory gene expression and phagocytosis were reduced, whereas production of ROS was stimulated.
Keywords: bone resorption; chemically modified curcumin/analogs and derivatives; dose-response relationship; inflammation; macrophages; periodontal disease.
© 2018 American Academy of Periodontology.
Similar articles
-
Differential effects of natural Curcumin and chemically modified curcumin on inflammation and bone resorption in model of experimental periodontitis.Arch Oral Biol. 2018 Jul;91:42-50. doi: 10.1016/j.archoralbio.2018.04.007. Epub 2018 Apr 10. Arch Oral Biol. 2018. PMID: 29669267
-
A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor κB Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis.Inflammation. 2017 Aug;40(4):1436-1449. doi: 10.1007/s10753-017-0587-4. Inflammation. 2017. PMID: 28534138
-
A novel chemically modified curcumin reduces inflammation-mediated connective tissue breakdown in a rat model of diabetes: periodontal and systemic effects.J Periodontal Res. 2017 Apr;52(2):186-200. doi: 10.1111/jre.12381. Epub 2016 Apr 1. J Periodontal Res. 2017. PMID: 27038334
-
Does Chemically Modified Curcumin Control the Progression of Periodontitis? A Systematic Review.J Exp Pharmacol. 2021 Jun 9;13:565-575. doi: 10.2147/JEP.S313192. eCollection 2021. J Exp Pharmacol. 2021. PMID: 34135646 Free PMC article. Review.
-
Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies.Biomed Res Int. 2022 May 2;2022:5832009. doi: 10.1155/2022/5832009. eCollection 2022. Biomed Res Int. 2022. PMID: 35547360 Free PMC article. Review.
Cited by
-
Advances of Oxidative Stress Impact in Periodontitis: Biomarkers and Effective Targeting Options.Curr Med Chem. 2024;31(38):6187-6203. doi: 10.2174/0109298673297545240507091410. Curr Med Chem. 2024. PMID: 38726786 Review.
-
AR-A014418, a glycogen synthase kinase-3β inhibitor, mitigates lipopolysaccharide-induced inflammation in rat dental pulp stem cells via NLR family pyrin domain containing 3 inflammasome impairment.J Dent Sci. 2023 Oct;18(4):1534-1543. doi: 10.1016/j.jds.2023.03.010. Epub 2023 Mar 22. J Dent Sci. 2023. PMID: 37799857 Free PMC article.
-
Evaluation of Immunohistochemical Biomarkers in Diabetic Wistar Rats with Periodontal Disease.J Pers Med. 2024 May 15;14(5):527. doi: 10.3390/jpm14050527. J Pers Med. 2024. PMID: 38793109 Free PMC article.
-
Study of the Osteoimmunomodulatory Properties of Curcumin-Modified Copper-Bearing Titanium.Molecules. 2022 May 17;27(10):3205. doi: 10.3390/molecules27103205. Molecules. 2022. PMID: 35630685 Free PMC article.
-
From Simple Mouth Cavities to Complex Oral Mucosal Disorders-Curcuminoids as a Promising Therapeutic Approach.ACS Pharmacol Transl Sci. 2021 Mar 17;4(2):647-665. doi: 10.1021/acsptsci.1c00017. eCollection 2021 Apr 9. ACS Pharmacol Transl Sci. 2021. PMID: 33860191 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources